This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/chemspider/
n30http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/chebi/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n7http://linked.opendata.cz/resource/drugbank/mixture/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/wikipedia/
n31http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/pubchem-compound/
n12http://www.rxlist.com/cgi/generic/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/resource/drugbank/medicinal-product/
n4http://linked.opendata.cz/ontology/mesh/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/drugbank/
n28http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/iuphar/
n6http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/guide-to-pharmacology/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01576/identifier/national-drug-code-directory/
n29http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01576
rdf:type
n3:Drug
n3:description
Dextroamphetamine is the dextrorotary stereoisomer of the amphetamine molecule, which can take two different forms. It is a slightly polar, weak base and is lipophilic.
n3:dosage
n8:271B5734-363D-11E5-9242-09173F13E4C5 n8:271B5735-363D-11E5-9242-09173F13E4C5 n8:271B5736-363D-11E5-9242-09173F13E4C5 n8:271B5737-363D-11E5-9242-09173F13E4C5 n8:271B5738-363D-11E5-9242-09173F13E4C5 n8:271B572D-363D-11E5-9242-09173F13E4C5 n8:271B572E-363D-11E5-9242-09173F13E4C5 n8:271B572F-363D-11E5-9242-09173F13E4C5 n8:271B5730-363D-11E5-9242-09173F13E4C5 n8:271B5731-363D-11E5-9242-09173F13E4C5 n8:271B5732-363D-11E5-9242-09173F13E4C5 n8:271B5733-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Yamada H, Baba T, Hirata Y, Oguri K, Yoshimura H: Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems. Xenobiotica. 1984 Nov;14(11):861-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6506758 # Warneke L: Psychostimulants in psychiatry. Can J Psychiatry. 1990 Feb;35(1):3-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2180548 # Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000 Jun;61(6):436-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10901342 # Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14520168 # Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, Cohen LG: Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol. 2002 Jan;51(1):59-68. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11782985
n3:group
illicit approved
n3:halfLife
10-28 hours (average is approximately 12 hours)
n3:indication
Used to treat attention deficit hyperactivity disorder (ADHD).
owl:sameAs
n27:DB01576 n31:DB01576
dcterms:title
Dextroamphetamine
adms:identifier
n14:PA449269 n15:46506252 n16:Dextroamphetamine n17:0007-3512-59 n18:5826 n19:C07884 n20:D03740 n21:2147 n22:2147 n23:DB01576 n24:4469 n25:5621
n3:mechanismOfAction
The exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect.
n3:packager
n9:271B5700-363D-11E5-9242-09173F13E4C5 n9:271B5701-363D-11E5-9242-09173F13E4C5 n9:271B56FF-363D-11E5-9242-09173F13E4C5 n9:271B5704-363D-11E5-9242-09173F13E4C5 n9:271B5705-363D-11E5-9242-09173F13E4C5 n9:271B5702-363D-11E5-9242-09173F13E4C5 n9:271B5703-363D-11E5-9242-09173F13E4C5 n9:271B5708-363D-11E5-9242-09173F13E4C5 n9:271B5709-363D-11E5-9242-09173F13E4C5 n9:271B5706-363D-11E5-9242-09173F13E4C5 n9:271B5707-363D-11E5-9242-09173F13E4C5 n9:271B570C-363D-11E5-9242-09173F13E4C5 n9:271B570D-363D-11E5-9242-09173F13E4C5 n9:271B570A-363D-11E5-9242-09173F13E4C5 n9:271B570B-363D-11E5-9242-09173F13E4C5 n9:271B5713-363D-11E5-9242-09173F13E4C5 n9:271B5710-363D-11E5-9242-09173F13E4C5 n9:271B5714-363D-11E5-9242-09173F13E4C5 n9:271B5711-363D-11E5-9242-09173F13E4C5 n9:271B570E-363D-11E5-9242-09173F13E4C5 n9:271B570F-363D-11E5-9242-09173F13E4C5 n9:271B5717-363D-11E5-9242-09173F13E4C5 n9:271B5718-363D-11E5-9242-09173F13E4C5 n9:271B5715-363D-11E5-9242-09173F13E4C5 n9:271B5712-363D-11E5-9242-09173F13E4C5 n9:271B5716-363D-11E5-9242-09173F13E4C5
n3:synonym
(S)-(+)-Amphetamine (S)-1-Phenyl-2-propylamine Dextroamphetamine dexamphetamine (S)-(+)-beta-Phenylisopropylamine (AlphaS)-alpha-methylbenzeneethanamine (S)-amphetamine (+)-(S)-amphetamine d-amphetamine (S)-alpha-Methylbenzeneethanamine (+)-alpha-Methylphenylethylamine (S)-1-Phenyl-2-aminopropane (+)-alpha-Methylphenethylamine (+)-Amphetamine
n3:toxicity
In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg. Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.
n29:hasAHFSCode
n30:28-20-04
n3:mixture
n7:271B56FE-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French Laboratories.
n4:hasConcept
n5:M0006134
foaf:page
n12:dextroamphetamine.htm n28:dextroamphetamine.html
n3:IUPAC-Name
n6:271B573D-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B5743-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B5742-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B573F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B5740-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B5741-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B573B-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B5754-363D-11E5-9242-09173F13E4C5 n6:271B5739-363D-11E5-9242-09173F13E4C5 n6:271B573C-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B573A-363D-11E5-9242-09173F13E4C5
n3:pKa
n6:271B5755-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n6:271B5749-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B574A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B5744-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B5745-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B5747-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B5746-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B5748-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral bioavailability is over 75%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51-64-9
n3:category
n3:containedIn
n10:271B5719-363D-11E5-9242-09173F13E4C5 n10:271B571A-363D-11E5-9242-09173F13E4C5 n10:271B571D-363D-11E5-9242-09173F13E4C5 n10:271B571E-363D-11E5-9242-09173F13E4C5 n10:271B571B-363D-11E5-9242-09173F13E4C5 n10:271B571C-363D-11E5-9242-09173F13E4C5 n10:271B5721-363D-11E5-9242-09173F13E4C5 n10:271B5722-363D-11E5-9242-09173F13E4C5 n10:271B571F-363D-11E5-9242-09173F13E4C5 n10:271B5720-363D-11E5-9242-09173F13E4C5 n10:271B5724-363D-11E5-9242-09173F13E4C5 n10:271B5725-363D-11E5-9242-09173F13E4C5 n10:271B5723-363D-11E5-9242-09173F13E4C5 n10:271B5728-363D-11E5-9242-09173F13E4C5 n10:271B5729-363D-11E5-9242-09173F13E4C5 n10:271B5726-363D-11E5-9242-09173F13E4C5 n10:271B5727-363D-11E5-9242-09173F13E4C5 n10:271B572C-363D-11E5-9242-09173F13E4C5 n10:271B572A-363D-11E5-9242-09173F13E4C5 n10:271B572B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B574E-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n6:271B5753-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B5750-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B5751-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n6:271B5752-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B574D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B574C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B574F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B573E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B574B-363D-11E5-9242-09173F13E4C5